Product Program year 2023 Source: CMS Open Payments

Tykerb

Drug Oncology

NDC 0078-0671-19

Open in the dashboard

General payments

$0

0 payments

Research payments

$1,335,584

38 payments

Through program year 2023, $0 in general payments and $1,335,584 in research payments were reported against Tykerb (Oncology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

5 rows
Year Kind Amount Payments
2023 Research $1,500 1
2022 Research $496,931 7
2021 Research $497,009 16
2020 Research $338,002 13
2019 Research $2,142 1

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

169

Prescriptions dispensed, refills included

Drug cost

$1,372,394

Paid at the pharmacy, in all

Prescribers

14

With 11 or more claims of it

Medicare Part D drugs matched to TYKERB, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Tykerb Lapatinib Ditosylate Same name 14 169 $1,372,394

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 14 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Qamar Khan Hematology-Oncology KS 14 $109,416 None on record
Kaye Kawahara Hematology-Oncology HI 13 $126,717 None on record
Alessandra Fitzpatrick Physician Assistant MD 13 $107,682 None on record
Roberto Rodriguez Hematology-Oncology KS 12 $134,342 None on record
Lowell Hart Hematology-Oncology FL 12 $120,234 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See all 14 in the dashboard with a free account
38 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record